China In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012

Product Code GMD15219
Publication Date October 2008
Publisher Global Markets Direct
Product Type Report
Pages 142
ISBN Number not applicable
Change currency
PDF £1,895.00 €2,282 $2,996 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

China In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012

This report is an essential source for in-depth information and data relating to the China In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the In vitro diagnostic dvices in China

Scope

  • The report provides in vitro diagnostics information broken down into detailed categories and segments in China.
  • Total revenues, end users
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the in vitro diagnostics devices market in China.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets Covered in the Report
    • 3.1 In Vitro Diagnostics Devices
    • 3.2 Clinical Chemistry Test Reagents
      • 3.2.1 Laboratory Reagents
      • 3.2.2 Clinical Chemistry Calibrators and Controls
      • 3.2.3 Clinical Chemistry Rapid Tests
    • 3.3 Immunochemistry Test Reagents
      • 3.3.1 Disease Specific Markers
        • 3.3.1.1 Tumor Markers
        • 3.3.1.2 Cardiac Markers
      • 3.3.2 Disease Specific Test Reagents
        • 3.3.2.1 Auto-Immune Disease
        • 3.3.2.2 Rheumatoid Disease
        • 3.3.2.3 Anemia/ Vitamins
        • 3.3.2.4 Allergy
      • 3.3.3 Drug Related Testing Reagents
        • 3.3.3.1 Therapeutic Drugs
        • 3.3.3.2 Drug of Abuse and Toxicology
      • 3.3.4 Hormone Related Testing Reagents
        • 3.3.4.1 Specific Proteins
        • 3.3.4.2 Fertility and Pregnancy
        • 3.3.4.3 Individual/Specified hormones
        • 3.3.4.4 Specific Organ Function
      • 3.3.5 Immunochemistry Calibrators and Controls
      • 3.3.6 Immunochemistry Rapid Tests
    • 3.4 Blood Test Reagents
      • 3.4.1 Hematology Test Reagents
        • 3.4.1.1 Hematology
        • 3.4.1.2 Immunohaematology
        • 3.4.1.3 Hematology Calibrators and Controls
        • 3.4.1.4 Immunohaematology Controls
      • 3.4.2 Hemostasis Test Reagents
        • 3.4.2.1 Hemostasis
        • 3.4.2.2 Hemostasis Calibrators and Controls
        • 3.4.2.3 Hemostasis Rapid Tests
      • 3.4.3 Tissue Typing Reagents
      • 3.4.4 Monoclonal Antibodies
      • 3.4.5 Cytokines and Immunomodulators
      • 3.4.6 Histology and Cytology Reagents
    • 3.5 Microbiology Test Reagents
      • 3.5.1 Bacteriology Test Reagents
        • 3.5.1.1 Bacteriology Culture
        • 3.5.1.2 Blood Culture
        • 3.5.1.3 Bacteriology Identification and Susceptibility
      • 3.5.2 Microbiology Calibrators and Controls
      • 3.5.3 Microbiology Rapid Tests
    • 3.6 Infectious Immunology Test Reagents
      • 3.6.1 Bacteriology
      • 3.6.2 Virology
        • 3.6.2.1 Hepatitis Viruses
        • 3.6.2.2 Retroviruses
      • 3.6.3 Parasitology
      • 3.6.4 Infectious Immunology Calibrators and Controls
      • 3.6.5 Infectious Immunology Rapid Tests
    • 3.7 Genetic Test Reagents
    • 3.8 Self Testing
    • 3.9 Instruments
  • 4 Healthcare Sector Review
    • 4.1 Healthcare Expenditure
    • 4.2 Healthcare Infrastructure
      • 4.2.1 Healthcare Personnel Data
      • 4.2.2 Healthcare Facilities Data
    • 4.3 Healthcare Policy
  • 5 Regulation System
    • 5.1 Medical Equipment Approval Process
      • 5.1.1 Classification
      • 5.1.2 Registration and Conformity assessment
      • 5.1.3 China Compulsory Certificate (CCC Mark)
      • 5.1.4 Labeling and Packaging
      • 5.1.5 Registration Fee
      • 5.1.6 Registration Period
    • 5.2 Post Market Surveillance (PMS)
  • 6 Pricing and Reimbursement
  • 7 Distribution Structure
  • 8 In Vitro Diagnostics In China
    • 8.1 In Vitro Diagnostics, China, Overall Revenues ($ mn), 2000-2012
    • 8.2 In Vitro Diagnostics, China, Company Share (2006-2007)
  • 9 Blood Test Reagents In China
    • 9.1 Blood Test Reagents Overall Revenue (2000-2012)
      • 9.1.1 Haematology Test Reagents Revenue (2000-2012)
      • 9.1.2 Hemostasis Test Reagents Revenue (2000-2012)
    • 9.2 Blood Test Reagents Distribution Share (2006-2007)
    • 9.3 Blood Test Reagents, China, Company Share (2006-2007)
  • 10 Clinical Chemistry Test Reagents In China
    • 10.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2012)
    • 10.2 Clinical Chemistry Test Reagents Distribution Share (2006-2007)
    • 10.3 Clinical Chemistry Test Reagents, China, Company Share (2006-2007)
  • 11 Genetic Test Reagents In China
    • 11.1 Genetic Test Reagents Overall Revenue (2000-2012)
    • 11.2 Genetic Test Reagents Distribution Share (2006-2007)
    • 11.3 Genetic Test Reagents, China, Company Share (2006-2007)
  • 12 Immunochemistry Test Reagents In China
    • 12.1 Immunochemistry Test Reagents Overall Revenue (2000-2012)
      • 12.1.1 Disease Specific Markers Revenue (2000-2012)
      • 12.1.2 Disease Specific Test Reagents (2000-2012)
      • 12.1.3 Drug Related Testing Reagents Revenue (2000-2012)
      • 12.1.4 Hormone Related Testing Reagents Revenue (2000-2012)
    • 12.2 Immunochemistry Test Reagents Distribution Share (2006-2007)
    • 12.3 Immunochemistry Test Reagents, China, Company Share (2006-2007)
  • 13 Infectious Immunology Test Reagents In China
    • 13.1 Infectious Immunology Test Reagents Overall Revenue (2000-2012)
      • 13.1.1 Virology Revenue (2000-2012)
    • 13.2 Infectious Immunology Test Reagents Distribution Share (2006-2007)
    • 13.3 Infectious Immunology Test Reagents, China, Company Share (2006-2007)
  • 14 Instruments In China
    • 14.1 Instruments Overall Revenue (2000-2012)
    • 14.2 Instruments Distribution Share (2006-2007)
    • 14.3 Instruments, China, Company Share (2006-2007)
  • 15 Microbiology Test Reagents In China
    • 15.1 Microbiology Test Reagents Overall Revenue (2000-2012)
      • 15.1.1 Bacteriology Test Reagents Revenue (2000-2012)
    • 15.2 Microbiology Test Reagents Distribution Share (2006-2007)
    • 15.3 Microbiology Test Reagents, China, Company Share (2006-2007)
  • 16 Self Testing In China
    • 16.1 Self Testing Overall Revenue (2000-2012)
    • 16.2 Self Testing Distribution Share (2006-2007)
    • 16.3 Self Testing, China, Company Share (2006-2007)
  • 17 F. Hoffmann-La Roche Ltd. Company Profile
    • 17.1 Company Overview
    • 17.2 Roche Diagnostics Ltd. Company Overview
    • 17.3 Value Chain Analysis
      • 17.3.1 Manufacturing
        • 17.3.1.1 In House Manufacturing
        • 17.3.1.2 Outsourcing
      • 17.3.2 Product Development
        • 17.3.2.1 Regulatory Approvals
        • 17.3.2.2 Clinical Trials
        • 17.3.2.3 Research and Development
      • 17.3.3 Sales and Marketing
        • 17.3.3.1 Partnerships and Alliances
        • 17.3.3.2 Licensing Agreements
    • 17.4 F. Hoffmann-La Roche Ltd. Pipeline Products
      • 17.4.1 F. Hoffmann-La Roche Ltd. Pipeline Products by Equipment Type
      • 17.4.2 F. Hoffmann-La Roche Ltd. Pipeline Products by Development Stage
      • 17.4.3 F. Hoffmann-La Roche Ltd. Pipeline Products by Therapy Area
      • 17.4.4 F. Hoffmann-La Roche Ltd. Pipeline Products by Clinical Trials
      • 17.4.5 F. Hoffmann-La Roche Ltd. Pipeline Products by News Summary
  • 18 Abbott Laboratories Company Profile
    • 18.1 Company Overview
    • 18.2 Value Chain Analysis
      • 18.2.1 Manufacturing
        • 18.2.1.1 In House Manufacturing
      • 18.2.2 Product Development
        • 18.2.2.1 Regulatory Approvals
        • 18.2.2.2 Research and Development
        • 18.2.2.3 Clinical Trials
      • 18.2.3 Sales and Marketing
        • 18.2.3.1 Partnerships and Alliances
  • 19 Beckman Coulter, Inc. Company Profile
    • 19.1 Company Overview
    • 19.2 Value Chain Analysis
      • 19.2.1 Manufacturing
        • 19.2.1.1 In House Manufacturing
      • 19.2.2 Product Development
        • 19.2.2.1 Regulatory Approvals
        • 19.2.2.2 Research and Development
      • 19.2.3 Sales and Marketing
        • 19.2.3.1 Partnerships and Alliances
        • 19.2.3.2 Licensing Agreements
    • 19.3 Beckman Coulter, Inc. Pipeline Products
      • 19.3.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type
      • 19.3.2 Beckman Coulter, Inc. Pipeline Products By Development Stage
      • 19.3.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area
      • 19.3.4 Beckman Coulter, Inc. Pipeline Products By News Summary
  • 20 Ortho-Clinical Diagnostics Inc. Company Profile
    • 20.1 Company Overview
  • 21 Dade Behring Holdings, Inc. Company Profile
    • 21.1 Company Overview
    • 21.2 Dade Behring Holdings, Inc. Pipeline Products
      • 21.2.1 Dade Behring Holdings, Inc. Pipeline Products By Equipment Type
      • 21.2.2 Dade Behring Holdings, Inc. Pipeline Products By Development Stage
      • 21.2.3 Dade Behring Holdings, Inc. Pipeline Products By Therapy Area
      • 21.2.4 Dade Behring Holdings, Inc. Pipeline Products By News Summary
  • 22 bioMerieux S.A. Company Profile
    • 22.1 Company Overview
    • 22.2 Value Chain Analysis
      • 22.2.1 Manufacturing
        • 22.2.1.1 In House Manufacturing
      • 22.2.2 Product Development
        • 22.2.2.1 Regulatory Approvals
        • 22.2.2.2 Clinical Trials
        • 22.2.2.3 Research and Development
      • 22.2.3 Sales and Marketing
        • 22.2.3.1 Partnerships and Alliances
        • 22.2.3.2 Licensing Agreements
  • 23 Beijing Bio-Ekon Biotechnology Co., Ltd. Company Profile
    • 23.1 Company Overview
  • 24 Beijing Pason Pharmaceuticals Inc. Company Profile
    • 24.1 Company Overview
  • 25 China Medical Technologies, Inc. Company Profile
    • 25.1 Company Overview
    • 25.2 China Medical Technologies, Inc. Pipeline Products
      • 25.2.1 China Medical Technologies, Inc. Pipeline Products By Equipment Type
      • 25.2.2 China Medical Technologies, Inc. Pipeline Products By Development Stage
      • 25.2.3 China Medical Technologies, Inc. Pipeline Products By Therapy Area
      • 25.2.4 China Medical Technologies, Inc. Pipeline Products By Clinical Trials
      • 25.2.5 China Medical Technologies, Inc. Pipeline Products By News Summary
  • 26 Jingmei Biotech Co.,Ltd. Company Profile
    • 26.1 Company Overview
  • 27 Mindray Medical International Limited Company Profile
    • 27.1 Company Overview
    • 27.2 Mindray Medical International Limited Pipeline Products
      • 27.2.1 Mindray Medical International Limited Pipeline Products By Equipment Type
      • 27.2.2 Mindray Medical International Limited Pipeline Products By Development Stage
      • 27.2.3 Mindray Medical International Limited Pipeline Products By Therapy Area
      • 27.2.4 Mindray Medical International Limited Pipeline Products By News Summary
  • 28 Shanghai Genomics, Inc. Company Profile
    • 28.1 Company Overview
  • 29 Financial Deals Landscape
    • 29.1 Venture Financing
      • 29.1.1 Progentech Limited Secures $21 Million In Series C Financing
    • 29.2 IPO
      • 29.2.1 China Medical Technologies Prices Public Offering Of $225.6 Million
    • 29.3 Debt Offerings
      • 29.3.1 China Medical Technologies Prices Public Offering Of $240 Million
  • 30 Appendix
    • 30.1 Global Markets Direct Research Methodology
    • 30.2 Coverage
    • 30.3 Secondary Research
    • 30.4 Primary Research
    • 30.5 Models
    • 30.6 Forecasts
    • 30.7 Expert Panels
    • 30.8 Currency Conversion
    • 30.9 Contact Us
    • 30.10 Disclaimer
  • 1 List of Tables
    • Table 1: Doctors by Specialty in China, 2003-2007
    • Table 2: Hospital Wards by Specialty in China, 2003 - 2007
    • Table 3: Healthcare Institutions in China, 2000-2004
    • Table 4: Personnel Employed in Healthcare Institutions in China, 2000-2004
    • Table 5: Healthcare Institutions, Hospital Beds and Employed Personnel by Region in China, 2004
    • Table 6: In Vitro Diagnostics, China, Overall Revenues ($ mn), 2000-2012
    • Table 7: In Vitro Diagnostics, China, Overall Revenues ($ mn), 2000-2012
    • Table 8: In Vitro Diagnostics, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 9: In Vitro Diagnostics, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 10: In Vitro Diagnostics, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 11: Blood Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 12: Blood Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 13: Haematology Test Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 14: Haematology Test Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Table 15: Hemostasis Test Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 16: Hemostasis Test Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Table 17: Blood Test Reagents, China, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 18: Blood Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 19: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 20: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 21: Clinical Chemistry Test Reagents, China, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 22: Clinical Chemistry Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 23: Genetic Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 24: Genetic Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 25: Genetic Test Reagents, China, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 26: Genetic Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 27: Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 28: Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 29: Disease Specific Markers, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 30: Disease Specific Markers, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Table 31: Disease Specific Test Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 32: Disease Specific Test Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Table 33: Drug Related Testing Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 34: Drug Related Testing Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Table 35: Hormone Related Testing Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 36: Hormone Related Testing Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Table 37: Immunochemistry Test Reagents, China, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 38: Immunochemistry Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 39: Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 40: Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 41: Virology, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 42: Virology, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Table 43: Infectious Immunology Test Reagents, China, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 44: Infectious Immunology Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 45: Instruments, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 46: Instruments, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 47: Instruments, China, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 48: Instruments, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 49: Microbiology Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 50: Microbiology Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 51: Bacteriology Test Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 52: Bacteriology Test Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Table 53: Microbiology Test Reagents, China, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 54: Microbiology Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 55: Self Testing, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 56: Self Testing, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 57: Self Testing, China, Distribution Share by Revenue ($ mn), 2006-2007
    • Table 58: Self Testing, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 59: F. Hoffmann-La Roche Ltd. Pipeline Products by Equipment Type
    • Table 60: F. Hoffmann-La Roche Ltd. Pipeline Products By Development Stage
    • Table 61: F. Hoffmann-La Roche Ltd. Pipeline Products By Therapy Area
    • Table 62: F. Hoffmann-La Roche Ltd. Pipeline Products By Clinical Trials
    • Table 63: F. Hoffmann-La Roche Ltd. Pipeline Products By News Summaries
    • Table 64: Beckman Coulter, Inc. Pipeline Products by Equipment Type
    • Table 65: Beckman Coulter, Inc. Pipeline Products By Development Stage
    • Table 66: Beckman Coulter, Inc. Pipeline Products By Therapy Area
    • Table 67: Beckman Coulter, Inc. Pipeline Products By News Summaries
    • Table 68: Dade Behring Holdings, Inc. Pipeline Products by Equipment Type
    • Table 69: Dade Behring Holdings, Inc. Pipeline Products by Development Stage
    • Table 70: Dade Behring Holdings, Inc. Pipeline Products By Therapy Area
    • Table 71: Dade Behring Holdings, Inc. Pipeline Products By News Summaries
    • Table 72: China Medical Technologies, Inc. Pipeline Products by Equipment Type
    • Table 73: China Medical Technologies, Inc. Pipeline Products By Development Stage
    • Table 74: China Medical Technologies, Inc. Pipeline Products By Therapy Area
    • Table 75: China Medical Technologies, Inc. Pipeline Products By Clinical Trials
    • Table 76: China Medical Technologies, Inc. Pipeline Products By News Summaries
    • Table 77: Mindray Medical International Limited Pipeline Products by Equipment Type
    • Table 78: Mindray Medical International Limited Pipeline Products By Development Stage
    • Table 79: Mindray Medical International Limited Pipeline Products By Therapy Area
    • Table 80: Mindray Medical International Limited Pipeline Products By News Summaries
    • Table 81: Currency Conversion from USD to Local Currency at 2007 Constant Rate
    • 1.2 List of Figures
    • Figure 1: Total Healthcare Expenditure in China, 2000 - 2005
    • Figure 2: Medical Equipment Registration Process in China, 2007
    • Figure 3: CCC Mark Certification Process in China, 2007
    • Figure 4: In Vitro Diagnostics, China, Overall Revenues ($ mn), 2000-2012
    • Figure 5: In Vitro Diagnostics, China, Portfolio Analysis, 2007
    • Figure 6: In Vitro Diagnostics, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 7: In Vitro Diagnostics, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 8: In Vitro Diagnostics, China, Company Share (%), 2007
    • Figure 9: Blood Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 10: Blood Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 11: Haematology Test Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 12: Haematology Test Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 13: Hemostasis Test Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 14: Hemostasis Test Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 15: Blood Test Reagents, China, Company Share (%), 2007
    • Figure 16: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 17: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 18: Clinical Chemistry Test Reagents, China, Company Share (%), 2007
    • Figure 19: Genetic Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 20: Genetic Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 21: Genetic Test Reagents, China, Company Share (%), 2007
    • Figure 22: Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 23: Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 24: Disease Specific Markers, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 25: Disease Specific Markers, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 26: Disease Specific Test Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 27: Disease Specific Test Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 28: Drug Related Testing Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 29: Drug Related Testing Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 30: Hormone Related Testing Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 31: Hormone Related Testing Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 32: Immunochemistry Test Reagents, China, Company Share (%), 2007
    • Figure 33: Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 34: Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 35: Virology, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 36: Virology, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 37: Infectious Immunology Test Reagents, China, Company Share (%), 2007
    • Figure 38: Instruments, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 39: Instruments, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 40: Instruments, China, Company Share (%), 2007
    • Figure 41: Microbiology Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 42: Microbiology Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 43: Bacteriology Test Reagents, China, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 44: Bacteriology Test Reagents, China, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012
    • Figure 45: Microbiology Test Reagents, China, Company Share (%), 2007
    • Figure 46: Self Testing, China, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 47: Self Testing, China, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 48: Self Testing, China, Company Share (%), 2007
    • Figure 49: F. Hoffmann-La Roche Ltd Value Chain Analysis
    • Figure 50: Abbott Laboratories Value Chain Analysis
    • Figure 51: Beckman Coulter, Inc. Value Chain Analysis
    • Figure 52: Biomerieux Sa Value Chain Analysis
    • Figure 53: Global Markets Direct Methodology